ObesityOBAEGNCT07283354
Comparison of Acceleromyography and Electromyography in Obese Patients Undergoing General Anesthesia
An observational study of Obesity, run by University of Padova at 1 site in Italy.
Trial summary
The goal of this prospective observational study is to compare two different methods of monitoring muscle relaxation during anesthesia - acceleromyography (AMG) and electromyography (EMG) - in people with obesity who are having bariatric surgery with general anesthesia and the muscle relaxant rocuronium. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Obesity
- What is being tested?
- Neuromuscular monitoring with electromyography (EMG) and Neuromuscular monitoring with acceleromyography (AMG)
- Type of treatment
- Surgery or procedure
- How many people
- 30 participants
- Where
- 1 siteItaly
- Study dates
- 1 Feb 2026to 30 Sep 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults aged 18-65 years with pathological obesity (Class II with comorbidities or Class III) scheduled for bariatric surgery under general anesthesia.
Who may be able to join
- Adults aged 18-65 years
- Pathological obesity (Class II with comorbidities or Class III)
- Scheduled for bariatric surgery under general anesthesia
- Written informed consent obtained
Who cannot join
- Severe acute or chronic respiratory disease (e.g., asthma, COPD, severe restrictive disease)
- Severe acute or recent cardiac disease (e.g., acute or recent myocardial infarction, inducible ischemia, heart failure)
- End-stage hepatic or renal disease
- Intolerance, allergy, or contraindication to study-related drugs
- Absence of informed consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site
Azienda Ospedale - Università di Padova (Padua University Hospital)
Padova, PD, 35127
Michele Carron, +390498213090, michele.carron@unipd.it
About this study
Official title: Comparison of Acceleromyography and Electromyography in Obese Patients Undergoing General Anesthesia With Rocuronium: A Prospective Observational Study
The goal of this prospective observational study is to compare two different methods of monitoring muscle relaxation during anesthesia - acceleromyography (AMG) and electromyography (EMG) - in people with obesity who are having bariatric surgery with general anesthesia and the muscle relaxant rocuronium.
The main question is: Which method is more accurate and precise in measuring the Train-of-Four (TOF) ratio during surgery? As part of this comparison, researchers will also note how quickly each method detects recovery of muscle function after the reversal drug sugammadex.
Read more
Participants will:
- Receive standard anesthesia care for bariatric surgery, including rocuronium to relax the muscles.
- Have two small monitoring devices applied, one to each hand: AMG on one hand, EMG on the other.
- Be monitored for muscle function during surgery and after receiving sugammadex to reverse the muscle relaxation.
Researchers will also record how easy each device is to use and whether participants have any breathing problems after surgery.
- Conditions
- Obesity
- Being tested
- Neuromuscular monitoring with electromyography (EMG), Neuromuscular monitoring with acceleromyography (AMG)
- Keywords
- Bariatric Surgery, General Anesthesia, Neuromuscular Blockade, Neuromuscular Monitoring, Acceleromyography, Electromyography
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neuromuscular monitoring with electromyography (EMG)Procedure or surgery
Neuromuscular function will be assessed using an electromyography device applied to the hand. The device measures the electrical activity of muscles in response to ulnar nerve stimulation to calculate the Train-of-Four (TOF) ratio.
Neuromuscular monitoring with acceleromyography (AMG)Procedure or surgery
Neuromuscular function will be assessed using an acceleromyography device applied to the hand. The device measures the acceleration of thumb movement in response to ulnar nerve stimulation to calculate the Train-of-Four (TOF) ratio.
| Study group | Role | What they receive |
|---|---|---|
| Patients with obesity undergoing bariatric surgery | Adults with obesity scheduled for bariatric surgery under general anesthesia. Each participant will be monitored for neuromuscular function using both acceleromyography (AMG) and electromyography (EMG) during surgery and after administration of sugammadex. Receives: Procedure: Neuromuscular monitoring with electromyography (EMG); Procedure: Neuromuscular monitoring with acceleromyography (AMG) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean paired difference in TOF ratio (AMG vs EMG)
Mean difference between acceleromyography (AMG) and electromyography (EMG) measurements of the Train-of-Four (TOF) ratio (unitless) obtained from paired intraoperative recordings.
Measured: Intraoperative period
Secondary outcomes (9)
Time to optimal conditions for tracheal intubation
Time from rocuronium administration to achievement of optimal intubation conditions, defined as TOF count = 0 or deep block confirmed by post-tetanic count (PTC). Measured with both AMG and EMG.
Measured: From rocuronium administration to tracheal intubation (approximately 1-3 minutes).
Maintenance of deep neuromuscular block
Duration and stability of deep block (PTC < 5) maintained during anesthesia, as measured by AMG and EMG.
Measured: From induction of anesthesia to start of reversal with sugammadex (approximately 60-120 minutes)
Time to recovery of TOF ratio ≥ 0.9 after sugammadex
Time from administration of sugammadex to achievement of TOF ratio ≥ 0.9 with each monitoring method (AMG and EMG).
Measured: From administration of sugammadex to achievement of TOF ratio ≥ 0.9 (typically 1-5 minutes).
Usability and quality assessment of AMG and EMG monitoring
Overall usability rating using a five-point Likert scale (1 = extremely poor, 5 = optimal) for AMG and EMG monitoring devices.
Measured: At the end of anesthesia (single assessment).
Incidence of postoperative respiratory complications
Number of participants experiencing respiratory complications (e.g., hypoxemia, airway obstruction, reintubation, or need for assisted ventilation) in the post-anesthesia care unit (PACU).
Measured: Through PACU discharge (approximately 1-2 hours after surgery).
Perioperative changes in heart rate
Heart rate (beats per minute, bpm) measured at predefined intraoperative and postoperative time points.
Measured: From induction of anesthesia through PACU discharge.
Perioperative changes in mean arterial pressure
Mean arterial pressure (mmHg) measured at predefined intraoperative and postoperative time points
Measured: From induction of anesthesia through PACU discharge
Perioperative changes in oxygen saturation (SpO₂)
Oxygen saturation (SpO2), %) measured at predefined intraoperative and postoperative time points.
Measured: From induction of anesthesia through PACU discharge
Perioperative changes in perfusion index
Perfusion index (Unitless) measured at predefined intraoperative and postoperative time points.
Measured: From induction of anesthesia through PACU discharge.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Dec 2025
- Study start1 Feb 2026 (estimated)
- Primary completion30 Jul 2026 (estimated)
- Study completion30 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Padova
- Sponsor type
- University, hospital or other
- Collaborators
- University Hospital, Padua, Italy
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07283354
- Sponsor's protocol ID
- AOP3692_CET
- Other IDs
- 6296/EST/25
- Acronym
- OBAEG
- Status last verified
- Aug 2025
- First submitted
- 25 Nov 2025
- Last updated
- 15 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared. Aggregate, de-identified study results will be disseminated through peer-reviewed publications and conference presentations
Publications
Carron M, Safaee Fakhr B, Ieppariello G, Foletto M. Perioperative care of the obese patient. Br J Surg. 2020 Jan;107(2):e39-e55. doi: 10.1002/bjs.11447.
PubMed 31903602Wedemeyer Z, Michaelsen KE, Jelacic S, Silliman W, Lopez A, Togashi K, Bowdle A. Accuracy and Precision of Three Acceleromyographs, Three Electromyographs, and a Mechanomyograph Measuring the Train-of-four Ratio in the Absence of Neuromuscular Blocking Drugs. Anesthesiology. 2024 Aug 1;141(2):262-271. doi: 10.1097/ALN.0000000000005051.
PubMed 38728090Naguib M, Brull SJ, Johnson KB. Conceptual and technical insights into the basis of neuromuscular monitoring. Anaesthesia. 2017 Jan;72 Suppl 1:16-37. doi: 10.1111/anae.13738.
PubMed 28044330Fuchs-Buder T, Romero CS, Lewald H, Lamperti M, Afshari A, Hristovska AM, Schmartz D, Hinkelbein J, Longrois D, Popp M, de Boer HD, Sorbello M, Jankovic R, Kranke P. Peri-operative management of neuromuscular blockade: A guideline from the European Society of Anaesthesiology and Intensive Care. Eur J Anaesthesiol. 2023 Feb 1;40(2):82-94. doi: 10.1097/EJA.0000000000001769. Epub 2022 Nov 15.
PubMed 36377554
Study at a glance
From the registry record, last updated by the sponsor on 15 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Acceleromyography and Electromyography in Obese Patients Undergoing General Anesthesia With Rocuronium: A Prospective Observational Study
- ClinicalTrials.gov ID
- NCT07283354
- Acronym / sponsor ID
- OBAEG / AOP3692_CET
- Conditions
- Obesity
- Keywords
- Bariatric Surgery, General Anesthesia, Neuromuscular Blockade, Neuromuscular Monitoring, Acceleromyography, Electromyography
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- University of PadovaUniversity, hospital or other
- Collaborators
- University Hospital, Padua, Italy
- Study start
- 1 Feb 2026 (estimated)
- Primary completion
- 30 Jul 2026 (estimated)
- Study completion
- 30 Sep 2026 (estimated)
- First posted
- 15 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this prospective observational study is to compare two different methods of monitoring muscle relaxation during anesthesia - acceleromyography (AMG) and electromyography (EMG) - in people with obesity who are having bariatric surgery with general anesthesia and the muscle relaxant rocuronium.
The main question is: Which method is more accurate and precise in measuring the Train-of-Four (TOF) ratio during surgery? As part of this comparison, researchers will also note how quickly each method detects recovery of muscle function after the reversal drug sugammadex.
Participants will:
- Receive standard anesthesia care for bariatric surgery, including rocuronium to relax the muscles.
- Have two small monitoring devices applied, one to each hand: AMG on one hand, EMG on the other.
- Be monitored for muscle function during surgery and after receiving sugammadex to reverse the muscle relaxation.
Researchers will also record how easy each device is to use and whether participants have any breathing problems after surgery.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with obesity undergoing bariatric surgery | – | Procedure: Neuromuscular monitoring with electromyography (EMG), Procedure: Neuromuscular monitoring with acceleromyography (AMG)Adults with obesity scheduled for bariatric surgery under general anesthesia. Each participant will be monitored for neuromuscular function using both acceleromyography (AMG) and electromyography (EMG) during surgery and after administration of sugammadex. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults aged 18-65 years with pathological obesity (Class II with comorbidities or Class III) scheduled for bariatric surgery under general anesthesia.
Key inclusion criteria (4 listed)
- Adults aged 18-65 years
- Pathological obesity (Class II with comorbidities or Class III)
- Scheduled for bariatric surgery under general anesthesia
- Written informed consent obtained
Key exclusion criteria (5 listed)
- Severe acute or chronic respiratory disease (e.g., asthma, COPD, severe restrictive disease)
- Severe acute or recent cardiac disease (e.g., acute or recent myocardial infarction, inducible ischemia, heart failure)
- End-stage hepatic or renal disease
- Intolerance, allergy, or contraindication to study-related drugs
- Absence of informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neuromuscular monitoring with electromyography (EMG)Neuromuscular function will be assessed using an electromyography device applied to the hand. The device measures the electrical activity of muscles in response to ulnar nerve stimulation to calculate the Train-of-Four (TOF) ratio. | Procedure or surgery | Patients with obesity undergoing bariatric surgery |
| Neuromuscular monitoring with acceleromyography (AMG)Neuromuscular function will be assessed using an acceleromyography device applied to the hand. The device measures the acceleration of thumb movement in response to ulnar nerve stimulation to calculate the Train-of-Four (TOF) ratio. | Procedure or surgery | Patients with obesity undergoing bariatric surgery |
Primary outcome
Mean paired difference in TOF ratio (AMG vs EMG)
Time frame: Intraoperative period
Mean difference between acceleromyography (AMG) and electromyography (EMG) measurements of the Train-of-Four (TOF) ratio (unitless) obtained from paired intraoperative recordings.
9 secondary outcomes
Time to optimal conditions for tracheal intubation
Time frame: From rocuronium administration to tracheal intubation (approximately 1-3 minutes).
Maintenance of deep neuromuscular block
Time frame: From induction of anesthesia to start of reversal with sugammadex (approximately 60-120 minutes)
Time to recovery of TOF ratio ≥ 0.9 after sugammadex
Time frame: From administration of sugammadex to achievement of TOF ratio ≥ 0.9 (typically 1-5 minutes).
Usability and quality assessment of AMG and EMG monitoring
Time frame: At the end of anesthesia (single assessment).
Incidence of postoperative respiratory complications
Time frame: Through PACU discharge (approximately 1-2 hours after surgery).
Perioperative changes in heart rate
Time frame: From induction of anesthesia through PACU discharge.
Perioperative changes in mean arterial pressure
Time frame: From induction of anesthesia through PACU discharge
Perioperative changes in oxygen saturation (SpO₂)
Time frame: From induction of anesthesia through PACU discharge
Perioperative changes in perfusion index
Time frame: From induction of anesthesia through PACU discharge.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Dec 2025.
- Background: PubMed 31903602Carron M, Safaee Fakhr B, Ieppariello G, Foletto M. Perioperative care of the obese patient. Br J Surg. 2020 Jan;107(2):e39-e55. doi: 10.1002/bjs.11447.
- Background: PubMed 38728090Wedemeyer Z, Michaelsen KE, Jelacic S, Silliman W, Lopez A, Togashi K, Bowdle A. Accuracy and Precision of Three Acceleromyographs, Three Electromyographs, and a Mechanomyograph Measuring the Train-of-four Ratio in the Absence of Neuromuscular Blocking Drugs. Anesthesiology. 2024 Aug 1;141(2):262-271. doi: 10.1097/ALN.0000000000005051.
- Background: PubMed 28044330Naguib M, Brull SJ, Johnson KB. Conceptual and technical insights into the basis of neuromuscular monitoring. Anaesthesia. 2017 Jan;72 Suppl 1:16-37. doi: 10.1111/anae.13738.
- Background: PubMed 36377554Fuchs-Buder T, Romero CS, Lewald H, Lamperti M, Afshari A, Hristovska AM, Schmartz D, Hinkelbein J, Longrois D, Popp M, de Boer HD, Sorbello M, Jankovic R, Kranke P. Peri-operative management of neuromuscular blockade: A guideline from the European Society of Anaesthesiology and Intensive Care. Eur J Anaesthesiol. 2023 Feb 1;40(2):82-94. doi: 10.1097/EJA.0000000000001769. Epub 2022 Nov 15.
- Individual participant dataSharing planned: No. Individual participant data will not be shared. Aggregate, de-identified study results will be disseminated through peer-reviewed publications and conference presentations
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity, run by University of Padova at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 15 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Michele Carron, MD, PhD (+390498213090, michele.carron@unipd.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean paired difference in TOF ratio (AMG vs EMG) (time frame: Intraoperative period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07283354, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2025.